While clinical trials investigating the efficacy of vagus nerve stimulation or nicotine administration in COVID-19 for cholinergic anti-inflammatory pathway activation are ongoing, the impact of the expression of the dominant negative duplicate CHRFAM7A has never been considered. Here, CHRFAM7A is linked to COVID-19.